

Sean Emery

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/513293/publications.pdf>

Version: 2024-02-01

257
papers

20,922
citations

18482

62
h-index

10734

138
g-index

258
all docs

258
docs citations

258
times ranked

16893
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. <i>Journal of Infectious Diseases</i> , 2019, 219, 254-263. | 4.0 | 13 |
| 2 | Influence of <i>CYP3A5</i> and <i>SLCO1B1</i> polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients. <i>Pharmacogenomics</i> , 2019, 20, 517-527. | 1.3 | 3 |
| 3 | Impact of early antiretroviral treatment on sexual behaviour. <i>Aids</i> , 2019, 33, 2337-2350. | 2.2 | 2 |
| 4 | Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm ³ : Findings From the Strategic Timing of Antiretroviral Therapy (START) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 10-17. | 2.1 | 13 |
| 5 | ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 456-462. | 2.1 | 8 |
| 6 | Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. <i>Hepatology</i> , 2019, 69, 1135-1150. | 7.3 | 15 |
| 7 | Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. <i>HIV Medicine</i> , 2018, 19, 65-71. | 2.2 | 4 |
| 8 | Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2018, 5, e553-e559. | 4.7 | 19 |
| 9 | In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 708-717. | 2.3 | 8 |
| 10 | Changes in plasma lipidome following initiation of antiretroviral therapy. <i>PLoS ONE</i> , 2018, 13, e0202944. | 2.5 | 20 |
| 11 | Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. <i>Lancet HIV</i> , 2018, 5, e438-e447. | 4.7 | 337 |
| 12 | Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. <i>Clinical Trials</i> , 2017, 14, 264-276. | 1.6 | 30 |
| 13 | Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. <i>Aids</i> , 2017, 31, 953-963. | 2.2 | 72 |
| 14 | Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial. <i>Antiviral Therapy</i> , 2017, 23, 21-32. | 1.0 | 1 |
| 15 | Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 345-353. | 2.1 | 12 |
| 16 | Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. <i>Journal of Virology</i> , 2017, 91, . | 3.4 | 14 |
| 17 | Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 345-353. | 2.1 | 12 |
| 18 | Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial—The ENCORE1 Study. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 654-658. | 2.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. <i>Scientific Reports</i> , 2017, 7, 10934. | 3.3 | 36 |
| 20 | HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV. <i>Journal of Virology</i> , 2017, 91, . | 3.4 | 59 |
| 21 | Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. <i>Lancet HIV</i> ,the, 2017, 4, e13-e20. | 4.7 | 6 |
| 22 | Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx262. | 0.9 | 65 |
| 23 | Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx212. | 0.9 | 16 |
| 24 | HIV dynamics linked to memory CD4+ T cell homeostasis. <i>PLoS ONE</i> , 2017, 12, e0186101. | 2.5 | 11 |
| 25 | Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw213. | 0.9 | 15 |
| 26 | Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. <i>Lancet HIV</i> ,the, 2016, 3, e343-e350. | 4.7 | 26 |
| 27 | Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 122-132. | 5.8 | 21 |
| 28 | Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 841-850. | 1.1 | 13 |
| 29 | Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. <i>Lancet Respiratory Medicine</i> ,the, 2016, 4, 980-989. | 10.7 | 38 |
| 30 | An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2928-2937. | 3.0 | 7 |
| 31 | Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV. <i>Osteoporosis International</i> , 2016, 27, 1737-1745. | 3.1 | 12 |
| 32 | Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. <i>Clinical Pharmacokinetics</i> , 2016, 55, 861-873. | 3.5 | 51 |
| 33 | Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa. <i>Southern African Journal of HIV Medicine</i> , 2016, 17, 450. | 0.9 | 4 |
| 34 | Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2015, 16, 449-454. | 2.2 | 6 |
| 35 | Assessing site performance in the Altair study, a multinational clinical trial. <i>Trials</i> , 2015, 16, 138. | 1.6 | 13 |
| 36 | Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection. <i>PLoS ONE</i> , 2015, 10, e0118228. | 2.5 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Differences in the Direction of Change of Cerebral Function Parameters Are Evident over Three Years in HIV-Infected Individuals Electively Commencing Initial cART. PLoS ONE, 2015, 10, e0118608. | 2.5 | 11 |
| 38 | Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. PLoS ONE, 2015, 10, e0139981. | 2.5 | 45 |
| 39 | Why <scp>START</scp>? Reflections that led to the conduct of this large long-term strategic <scp>HIV</scp> trial. HIV Medicine, 2015, 16, 1-9. | 2.2 | 26 |
| 40 | Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-1 Infected Patients: Results of the ENCORE1 Study. Clinical Pharmacology and Therapeutics, 2015, 98, 406-416. | 4.7 | 72 |
| 41 | The impact of registration of clinical trials units: The UK experience. Clinical Trials, 2015, 12, 166-173. | 1.6 | 26 |
| 42 | Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Lancet HIV, 2015, 2, e42-e51. | 4.7 | 68 |
| 43 | Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial. Clinical Infectious Diseases, 2015, 60, 1026-1032. | 5.8 | 27 |
| 44 | Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. PLoS Medicine, 2015, 12, e1001809. | 8.4 | 119 |
| 45 | Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. New England Journal of Medicine, 2015, 373, 795-807. | 27.0 | 2,232 |
| 46 | Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels. Aids, 2015, 29, 911-919. | 2.2 | 37 |
| 47 | Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infectious Diseases, 2015, 15, 793-802. | 9.1 | 104 |
| 48 | Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Medicine, 2015, 16, 30-36. | 2.2 | 8 |
| 49 | Hip Structural Parameters over 96 Weeks in HIV-Infected Adults Switching Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 2014, 9, e94858. | 2.5 | 4 |
| 50 | Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy. PLoS ONE, 2014, 9, e95061. | 2.5 | 67 |
| 51 | Short Communication: CD4 T Cell Declines Occurring During Suppressive Antiretroviral Therapy Reflect Continued Production of Casp8p41. AIDS Research and Human Retroviruses, 2014, 30, 476-479. | 1.1 | 12 |
| 52 | Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation. Journal of the American Heart Association, 2014, 3, e000844. | 3.7 | 184 |
| 53 | Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. HIV Medicine, 2014, 15, 116-123. | 2.2 | 26 |
| 54 | HIV DNA Subspecies Persist in both Activated and Resting Memory CD4 ⁺ T Cells during Antiretroviral Therapy. Journal of Virology, 2014, 88, 3516-3526. | 3.4 | 76 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: design and methods. BMC Public Health, 2014, 14, 917. | 2.9 | 39 |
| 56 | Comparison of central and local HIV-1 RNA quantification from two international clinical trials. Aids, 2014, 28, 2480-2483. | 2.2 | 0 |
| 57 | Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. Aids, 2014, 28, 1791-1796. | 2.2 | 25 |
| 58 | Bone Mineral Density Over 96 Weeks in Adults Failing First-Line Therapy Randomized to Raltegravir/Lopinavir/Ritonavir Compared With Standard Second-Line Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 161-168. | 2.1 | 15 |
| 59 | A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy. HIV Medicine, 2014, 15, 442-448. | 2.2 | 2 |
| 60 | An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. Journal of Antimicrobial Chemotherapy, 2014, 69, 1104-1110. | 3.0 | 13 |
| 61 | Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: Results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. Journal of Electrocardiology, 2014, 47, 264-271. | 0.9 | 3 |
| 62 | Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet, The, 2014, 383, 1474-1482. | 13.7 | 144 |
| 63 | Factors Associated with D-Dimer Levels in HIV-Infected Individuals. PLoS ONE, 2014, 9, e90978. | 2.5 | 60 |
| 64 | HLA Alleles Association with Changes in Bone Mineral Density in HIV-1-Infected Adults Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 2014, 9, e93333. | 2.5 | 5 |
| 65 | Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies. PLoS ONE, 2014, 9, e101785. | 2.5 | 31 |
| 66 | Predictors of Clinical Progression in HIV-1-Infected Adults Initiating Combination Antiretroviral Therapy with Advanced Disease in the Asia-Pacific Region. Journal of the International Association of Providers of AIDS Care, 2013, 12, 270-277. | 1.5 | 2 |
| 67 | Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. Clinical Infectious Diseases, 2013, 57, 112-121. | 5.8 | 56 |
| 68 | Biomarkers and Electrocardiographic Evidence of Myocardial Ischemia in Patients With Human Immunodeficiency Virus Infection. American Journal of Cardiology, 2013, 111, 760-764. | 1.6 | 9 |
| 69 | The search for an HIV cure: tackling latent infection. Lancet Infectious Diseases, The, 2013, 13, 614-621. | 9.1 | 61 |
| 70 | Electrocardiographic Spatial QRS-T Angle and Incident Cardiovascular Disease in HIV-Infected Patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] Study). American Journal of Cardiology, 2013, 111, 118-124. | 1.6 | 6 |
| 71 | Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. Journal of NeuroVirology, 2013, 19, 383-392. | 2.1 | 11 |
| 72 | Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clinical Trials, 2013, 10, S5-S36. | 1.6 | 100 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Protease inhibitors and cardiac autonomic function in HIV-infected patients: a cross-sectional analysis from the Strategies for Management of Antiretroviral Therapy (SMART) Trial. <i>BMJ Open</i> , 2013, 3, e002523. | 1.9 | 3 |
| 74 | Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses. <i>Journal of Infectious Diseases</i> , 2013, 207, 1379-1388. | 4.0 | 39 |
| 75 | Results of External Quality Assessment for Proviral DNA Testing of HIV Tropism in the Maraviroc Switch Collaborative Study. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2063-2071. | 3.9 | 8 |
| 76 | Factors Associated With Adherence Amongst 5295 People Receiving Antiretroviral Therapy as Part of an International Trial. <i>Journal of Infectious Diseases</i> , 2013, 208, 40-49. | 4.0 | 72 |
| 77 | HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation. <i>Journal of the American Heart Association</i> , 2013, 2, e000264. | 3.7 | 59 |
| 78 | Reply to "Issues on Results of the External Quality Assessment for Proviral DNA Testing of HIV-1 Tropism in the Maraviroc Switch Collaborative Study". <i>Journal of Clinical Microbiology</i> , 2013, 51, 4287-4287. | 3.9 | 0 |
| 79 | Short Communication: HIV Blips While on Antiretroviral Therapy Can Indicate Consistently Detectable Viral Levels Due to Assay Underreporting. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1621-1625. | 1.1 | 7 |
| 80 | Predicting risk of cancer during HIV infection. <i>Aids</i> , 2013, 27, 1433-1441. | 2.2 | 158 |
| 81 | Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. <i>Aids</i> , 2013, 27, 2403-2411. | 2.2 | 38 |
| 82 | Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. <i>Aids</i> , 2013, 27, 973-979. | 2.2 | 315 |
| 83 | The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa. <i>PLoS ONE</i> , 2013, 8, e54435. | 2.5 | 2 |
| 84 | Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study. <i>PLoS ONE</i> , 2013, 8, e56249. | 2.5 | 18 |
| 85 | The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies. <i>PLoS ONE</i> , 2013, 8, e57121. | 2.5 | 54 |
| 86 | HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) + 2â€“3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy. <i>PLoS ONE</i> , 2013, 8, e77138. | 2.5 | 14 |
| 87 | Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study). <i>Journal of Infectious Diseases</i> , 2012, 206, 258-266. | 4.0 | 202 |
| 88 | Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1427-1433. | 3.2 | 32 |
| 89 | Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. <i>Aids</i> , 2012, 26, 543-550. | 2.2 | 62 |
| 90 | HIV Replication, Inflammation, and the Effect of Starting Antiretroviral Therapy on Plasma Asymmetric Dimethylarginine, a Novel Marker of Endothelial Dysfunction. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 128-134. | 2.1 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV. <i>Aids</i> , 2012, 26, 2337-2344. | 2.2 | 5 |
| 92 | A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, 143-149. | 2.1 | 19 |
| 93 | Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. <i>Aids</i> , 2012, 26, 1707-1717. | 2.2 | 8 |
| 94 | Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy. <i>Neuroradiology</i> , 2012, 54, 1331-1339. | 2.2 | 11 |
| 95 | Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. <i>PLoS ONE</i> , 2012, 7, e38377. | 2.5 | 97 |
| 96 | Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. <i>PLoS ONE</i> , 2012, 7, e44454. | 2.5 | 456 |
| 97 | Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. <i>HIV Medicine</i> , 2012, 13, 245-251. | 2.2 | 35 |
| 98 | Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease. <i>PLoS ONE</i> , 2012, 7, e24243. | 2.5 | 89 |
| 99 | Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection. <i>PLoS ONE</i> , 2012, 7, e43754. | 2.5 | 60 |
| 100 | Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: The INSIGHT FLU 002 and FLU 003 studies. <i>Vaccine</i> , 2011, 29, B56-B62. | 3.8 | 14 |
| 101 | Genotypic Resistance at Viral Rebound Among Patients Who Received Lopinavir/Ritonavir-Based or Efavirenz-Based First Antiretroviral Therapy in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 304-308. | 2.1 | 13 |
| 102 | Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. <i>Aids</i> , 2011, 25, 367-377. | 2.2 | 62 |
| 103 | The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool. <i>Aids</i> , 2011, 25, 1855-1863. | 2.2 | 23 |
| 104 | Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 36-43. | 2.1 | 142 |
| 105 | Empirical evaluation of the need for "on-going consent"™ in clinical research. <i>Aids</i> , 2011, 25, 107-114. | 2.2 | 9 |
| 106 | Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. <i>Aids</i> , 2011, 25, 2069-2078. | 2.2 | 69 |
| 107 | Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. <i>Aids</i> , 2011, 25, 2133-2142. | 2.2 | 45 |
| 108 | N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. <i>Aids</i> , 2011, 25, 651-657. | 2.2 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Haemoglobin and Anaemia in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 329-337. | 1.0 | 12 |
| 110 | Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 667-675. | 1.0 | 16 |
| 111 | Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). <i>HIV Medicine</i> , 2011, 12, 219-227. | 2.2 | 8 |
| 112 | Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial). <i>HIV Medicine</i> , 2011, 12, 602-609. | 2.2 | 5 |
| 113 | An Ad5-Vectored HIV-1 Vaccine Elicits Cell-mediated Immunity but does not Affect Disease Progression in HIV-1â€“infected Male Subjects: Results From a Randomized Placebo-Controlled Trial (The Step Study). <i>Journal of Infectious Diseases</i> , 2011, 203, 765-772. | 4.0 | 72 |
| 114 | Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 780-790. | 4.0 | 957 |
| 115 | Intensification of Antiretroviral Therapy With Raltegravir or Addition of Hyperimmune Bovine Colostrum in HIV-Infected Patients With Suboptimal CD4+ T-Cell Response: A Randomized Controlled Trial. <i>Journal of Infectious Diseases</i> , 2011, 204, 1532-1540. | 4.0 | 54 |
| 116 | Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 635-640. | 3.0 | 26 |
| 117 | Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. <i>Aids</i> , 2011, 25, 1727-1735. | 2.2 | 44 |
| 118 | Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial. <i>Aids</i> , 2011, 25, 1207-1217. | 2.2 | 40 |
| 119 | Higher Levels of CRP, D-dimer, IL-6, and Hyaluronic Acid Before Initiation of Antiretroviral Therapy (ART) Are Associated With Increased Risk of AIDS or Death. <i>Journal of Infectious Diseases</i> , 2011, 203, 1637-1646. | 4.0 | 287 |
| 120 | Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine. <i>PLoS ONE</i> , 2011, 6, e26885. | 2.5 | 5 |
| 121 | The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. <i>Aids</i> , 2010, 24, 353-563. | 2.2 | 13 |
| 122 | Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. <i>Aids</i> , 2010, 24, 1877-1886. | 2.2 | 66 |
| 123 | Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 480-490. | 3.8 | 33 |
| 124 | Frequent hepatitis B virus rebound among HIVâ€“hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010, 24, 857-865. | 2.2 | 59 |
| 125 | Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. <i>Aids</i> , 2010, 24, 2657-2663. | 2.2 | 49 |
| 126 | Smoking-Related Health Risks Among Persons With HIV in the Strategies for Management of Antiretroviral Therapy Clinical Trial. <i>American Journal of Public Health</i> , 2010, 100, 1896-1903. | 2.7 | 234 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Antiretroviral agents: Focus on Maraviroc for the Treatment of HIV-1-Infected Adults. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S5420. | 0.4 | 0 |
| 128 | Effects of Intermittent IL-2 Alone or with Peri-Cycle Antiretroviral Therapy in Early HIV Infection: The STALWART Study. <i>PLoS ONE</i> , 2010, 5, e9334. | 2.5 | 17 |
| 129 | Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. <i>Aids</i> , 2010, 24, 697-706. | 2.2 | 150 |
| 130 | Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatmentâ€Naive, HIVâ€Infected Subjects: Week 48 Data from the Altair Study. <i>Clinical Infectious Diseases</i> , 2010, 51, 855-864. | 5.8 | 57 |
| 131 | A Randomized Factorial Trial Comparing 4 Treatment Regimens in Treatmentâ€Naive HIVâ€Infected Persons with AIDS and/or a CD4 Cell Count <200 Cells/ μ L in South Africa. <i>Journal of Infectious Diseases</i> , 2010, 202, 1529-1537. | 4.0 | 30 |
| 132 | Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection. <i>Journal of Infectious Diseases</i> , 2010, 201, 1788-1795. | 4.0 | 724 |
| 133 | Phase coexistence near a morphotropic phase boundary in Sm-doped BiFeO ₃ films. <i>Applied Physics Letters</i> , 2010, 97, . | 3.3 | 77 |
| 134 | Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatmentâ€Naive, HIVâ€Infected Individuals Commencing cART? A Randomized, Controlled Study. <i>Clinical Infectious Diseases</i> , 2010, 50, 920-929. | 5.8 | 113 |
| 135 | A Novel Chemokine-Receptor-5 (CCR5) Blocker, SCH532706, Has Differential Effects on CCR5+CD4+and CCR5+CD8+T Cell Numbers in Chronic HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 653-661. | 1.1 | 14 |
| 136 | Detection of a Substantial Rate of Multidrugâ€Resistant Tuberculosis in an HIVâ€Infected Population in South Africa by Active Monitoring of Sputum Samples. <i>Clinical Infectious Diseases</i> , 2010, 50, 1053-1059. | 5.8 | 24 |
| 137 | Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a â€high-affinityâ€™ FcÎ³R1a genotype. <i>Aids</i> , 2010, 24, 1983-1990. | 2.2 | 37 |
| 138 | Changes in Lipids and Lipoprotein Particle Concentrations After Interruption of Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 275-284. | 2.1 | 14 |
| 139 | Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials. <i>HIV Clinical Trials</i> , 2010, 11, 205-219. | 2.0 | 41 |
| 140 | An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. <i>Hum Vaccin</i> , 2010, 6, 835-840. | 2.4 | 23 |
| 141 | Role of Interleukin-2 in Patients with HIV Infection. <i>Drugs</i> , 2010, 70, 1115-1130. | 10.9 | 26 |
| 142 | Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1878-1888. | 3.0 | 37 |
| 143 | Metabolic disorders and cardiovascular consequences of HIV infection and antiretroviral therapy. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 381-390. | 3.1 | 7 |
| 144 | High Levels of Human Antigen-Specific CD4+ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40). <i>Journal of Immunology</i> , 2009, 183, 2827-2836. | 0.8 | 153 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | Interruption of antiretroviral therapy is associated with increased plasma cystatin C. <i>Aids</i> , 2009, 23, 71-82. | 2.2 | 47 |
| 146 | Continuous antiretroviral therapy decreases bone mineral density. <i>Aids</i> , 2009, 23, 1519-1529. | 2.2 | 188 |
| 147 | Interleukin-2 Therapy in Patients with HIV Infection. <i>New England Journal of Medicine</i> , 2009, 361, 1548-1559. | 27.0 | 342 |
| 148 | Dietary Intake in HIV-Infected Men with Lipodystrophy: Relationships with Body Composition, Visceral Fat, Lipid, Glucose and Adipokine Metabolism. <i>Current HIV Research</i> , 2009, 7, 456-461. | 0.5 | 9 |
| 149 | Activation and Coagulation Biomarkers Are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV Infection. <i>Journal of Infectious Diseases</i> , 2009, 200, 973-983. | 4.0 | 140 |
| 150 | Evolution of CD4+ T Cell Count in HIV-1-Infected Adults Receiving Antiretroviral Therapy with Sustained Long-Term Virological Suppression. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 569-576. | 1.1 | 10 |
| 151 | Simplification of Antiretroviral Therapy with Tenofovir+Emtricitabine or Abacavir+Lamivudine: A Randomized, 96-Week Trial. <i>Clinical Infectious Diseases</i> , 2009, 49, 1591-1601. | 5.8 | 203 |
| 152 | A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. <i>Artificial Intelligence in Medicine</i> , 2009, 47, 63-74. | 6.5 | 55 |
| 153 | Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy. <i>HIV Medicine</i> , 2009, 10, 143-151. | 2.2 | 3 |
| 154 | Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up. <i>HIV Medicine</i> , 2009, 10, 163-172. | 2.2 | 11 |
| 155 | P15-01. Willingness to participate in actual preventive HIV vaccine phase I/IIa trial in Bangkok, Thailand. <i>Retrovirology</i> , 2009, 6, . | 2.0 | 1 |
| 156 | Lipoprotein particle subclasses, cardiovascular disease and HIV infection. <i>Atherosclerosis</i> , 2009, 207, 524-529. | 0.8 | 100 |
| 157 | Antiretroviral roll-out: the problem of second-line therapy. <i>Lancet, The</i> , 2009, 374, 185-186. | 13.7 | 18 |
| 158 | Raltegravir: a new choice in HIV and new chances for research. <i>Lancet, The</i> , 2009, 374, 764-766. | 13.7 | 15 |
| 159 | Immunotherapies in HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 188-193. | 3.8 | 15 |
| 160 | Improvements in antiretroviral therapy outcomes over calendar time. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 194-199. | 3.8 | 50 |
| 161 | Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. <i>Aids</i> , 2009, 23, 2222-2223. | 2.2 | 16 |
| 162 | Benefits and Burdens of Participation in a Longitudinal Clinical Trial. <i>Journal of Empirical Research on Human Research Ethics</i> , 2009, 4, 89-97. | 1.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 163 | Cancer: the effects of HIV and antiretroviral therapy, and implications for early antiretroviral therapy initiation. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 183-187. | 3.8 | 26 |
| 164 | Predicting the potential benefits of early initiation of ART: time to do a trial to find out. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 165-166. | 3.8 | 5 |
| 165 | A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients. <i>Antiviral Therapy</i> , 2009, 14, 111-115. | 1.0 | 9 |
| 166 | Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. <i>Lancet</i> , The, 2008, 372, 1881-1893. | 13.7 | 1,560 |
| 167 | HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a caseâ€“cohort analysis. <i>Lancet</i> , The, 2008, 372, 1894-1905. | 13.7 | 670 |
| 168 | Effect of Rosiglitazone on Peroxisome Proliferatorâ€“Activated Receptor Î³ Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drugâ€“Induced Mitochondrial Dysfunction. <i>Journal of Infectious Diseases</i> , 2008, 198, 1794-1803. | 4.0 | 33 |
| 169 | Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting. <i>International Journal of STD and AIDS</i> , 2008, 19, 529-532. | 1.1 | 22 |
| 170 | Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. <i>Aids</i> , 2008, 22, 2279-2289. | 2.2 | 64 |
| 171 | Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 26-34. | 2.1 | 28 |
| 172 | Major Clinical Outcomes in Antiretroviral Therapy (ART)â€“Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study. <i>Journal of Infectious Diseases</i> , 2008, 197, 1133-1144. | 4.0 | 364 |
| 173 | Disease Progression and Fatal Outcomes in HIVâ€“Infected Patients during Interruption of Antiretroviral Treatment. <i>Journal of Infectious Diseases</i> , 2008, 197, 775-775. | 4.0 | 5 |
| 174 | Inferior Clinical Outcome of the CD4+ Cell Countâ€“Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up. <i>Journal of Infectious Diseases</i> , 2008, 197, 1145-1155. | 4.0 | 191 |
| 175 | Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. <i>Clinical Infectious Diseases</i> , 2008, 47, 1468-1475. | 5.8 | 53 |
| 176 | Pneumonia in HIV-infected Persons. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 630-636. | 5.6 | 104 |
| 177 | Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. <i>Aids</i> , 2008, 22, F17-F24. | 2.2 | 300 |
| 178 | Episodic Antiretroviral Therapy Increases HIV Transmission Risk Compared With Continuous Therapy: Results of a Randomized Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 142-150. | 2.1 | 27 |
| 179 | Risk for Opportunistic Disease and Death after Reinitiating Continuous Antiretroviral Therapy in Patients with HIV Previously Receiving Episodic Therapy. <i>Annals of Internal Medicine</i> , 2008, 149, 289. | 3.9 | 118 |
| 180 | Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. <i>PLoS Medicine</i> , 2008, 5, e203. | 8.4 | 1,398 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. <i>Diabetes Care</i> , 2007, 30, 113-119. | 8.6 | 267 |
| 182 | Influence of IFN β Co-Expression on the Safety and Antiviral Efficacy of Recombinant Fowlpox Virus HIV Therapeutic Vaccines Following Interruption of Antiretroviral Therapy. <i>Hum Vaccin</i> , 2007, 3, 260-267. | 2.4 | 25 |
| 183 | A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 581-589. | 2.1 | 38 |
| 184 | Health-Related Quality of Life Outcomes in HIV-Infected Patients Starting Different Combination Regimens in a Randomized Multinational Trial: The INITIO-QoL Substudy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1215-1222. | 1.1 | 14 |
| 185 | Substantial Improvements in Performance Indicators Achieved in a Peripheral Blood Mononuclear Cell Cryopreservation Quality Assurance Program Using Single Donor Samples. <i>Vaccine Journal</i> , 2007, 14, 52-59. | 3.1 | 19 |
| 186 | The Safety, Efficacy, and Pharmacokinetic Profile of a Switch in Antiretroviral Therapy to Saquinavir, Ritonavir, and Atazanavir Alone for 48 Weeks and a Switch in the Saquinavir Formulation. <i>Clinical Infectious Diseases</i> , 2007, 44, 1475-1483. | 5.8 | 17 |
| 187 | Risk of cancers during interrupted antiretroviral therapy in the SMART study. <i>Aids</i> , 2007, 21, 1957-1963. | 2.2 | 113 |
| 188 | Project Phidisa: development of clinical research capacity within the South African National Defence Force. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 69-76. | 3.8 | 2 |
| 189 | Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. <i>Aids</i> , 2007, 21, 2445-2453. | 2.2 | 163 |
| 190 | Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. <i>Aids</i> , 2007, 21, 2315-2321. | 2.2 | 172 |
| 191 | Visceral and Subcutaneous Adiposity Measurements in Adults: Influence of Measurement Site. <i>Obesity</i> , 2007, 15, 1441-1447. | 3.0 | 24 |
| 192 | The development of artificial neural networks to predict virological response to combination HIV therapy. <i>Antiviral Therapy</i> , 2007, 12, 15-24. | 1.0 | 26 |
| 193 | Post-trial Access to Tested Interventions: The Views of IRB/REC Chair, Investigators, and Research Participants in a Multinational HIV/AIDS Study. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 837-841. | 1.1 | 20 |
| 194 | Therapeutic vaccination against HIV: current progress and future possibilities. <i>Clinical Science</i> , 2006, 110, 59-71. | 4.3 | 19 |
| 195 | Reporting and Evaluation of HIV-Related Clinical Endpoints in Two Multicenter International Clinical Trials. <i>HIV Clinical Trials</i> , 2006, 7, 125-141. | 2.0 | 18 |
| 196 | Evaluation of Subcutaneous Proleukin (Interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and Gender Differences in the Baseline Characteristics of Participants. <i>HIV Clinical Trials</i> , 2006, 7, 70-85. | 2.0 | 7 |
| 197 | A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. <i>Aids</i> , 2006, 20, 294-297. | 2.2 | 58 |
| 198 | Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. <i>HIV Medicine</i> , 2006, 7, 105-111. | 2.2 | 88 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Dose-Response Relationship of DNA and Recombinant Fowlpox Virus Prime-Boost HIV Vaccines: Implications for Future Trials. <i>Hum Vaccin</i> , 2006, 2, 134-136. | 2.4 | 13 |
| 200 | A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UKâ€“Vanguard Study. <i>PLOS Clinical Trials</i> , 2006, 1, e3. | 3.5 | 19 |
| 201 | A Randomised Trial Comparing Genotypic and Virtual Phenotypic Interpretation of HIV Drug Resistance: The CREST Study. <i>PLOS Clinical Trials</i> , 2006, 1, e18. | 3.5 | 26 |
| 202 | The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. <i>Clinical Trials</i> , 2006, 3, 119-132. | 1.6 | 8 |
| 203 | Short Communication: Nonnucleoside Reverse Transcriptase Inhibitor Fold Change or Plasma Concentration as a Predictor of Virological Response over 48 Weeks in Highly Treatment Experienced HIV-Positive Individuals. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 338-341. | 1.1 | 0 |
| 204 | Enfuvirtide in HIV-1-Infected Individuals Changing Therapy to A Nucleoside Reverse Transcriptase Inhibitor Sparing Regimen: The Alliance Study. <i>Antiviral Therapy</i> , 2006, 11, 409-419. | 1.0 | 10 |
| 205 | Buffalo Hump Seen in HIV-Associated Lipodystrophy is Associated With Hyperinsulinemia But Not Dyslipidemia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 156-162. | 2.1 | 50 |
| 206 | The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. <i>Aids</i> , 2005, 19, 1393-1399. | 2.2 | 28 |
| 207 | Randomised, Placebo-Controlled, Phase I/IIa Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon- γ in HIV-1 Infected Subjects. <i>Hum Vaccin</i> , 2005, 1, 232-238. | 2.4 | 29 |
| 208 | HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. <i>Aids</i> , 2005, 19, 169-178. | 2.2 | 29 |
| 209 | In Vivo, Nucleoside Reverseâ€“Transcriptase Inhibitors Alter Expression of Both Mitochondrial and Lipid Metabolism Genes in the Absence of Depletion of Mitochondrial DNA. <i>Journal of Infectious Diseases</i> , 2005, 191, 1686-1696. | 4.0 | 162 |
| 210 | Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 380-387. | 3.0 | 59 |
| 211 | Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial. <i>Aids</i> , 2005, 19, 1325-1327. | 2.2 | 21 |
| 212 | The Quality of Informed Consent in a Clinical Research Study in Thailand. <i>IRB: Ethics & Human Research</i> , 2005, 27, 9. | 0.8 | 44 |
| 213 | Informed Consent: Practices and Views of Investigators in a Multinational Clinical Trial. <i>IRB: Ethics & Human Research</i> , 2005, 27, 13. | 0.8 | 9 |
| 214 | Influence of Rosiglitazone on Flow-Mediated Dilatation and Other Markers of Cardiovascular Risk in HIV-Infected Patients with Lipoatrophy. <i>Antiviral Therapy</i> , 2005, 10, 135-143. | 1.0 | 22 |
| 215 | CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Meta-analysis of 3 Vanguard Studies. <i>Clinical Infectious Diseases</i> , 2004, 39, 115-122. | 5.8 | 109 |
| 216 | A Phase I Study of the Pharmacokinetics and Safety of Passive Immunotherapy with Caprine Anti-HIV Antibodies, PEHRG214, in HIV-1-Infected Individuals. <i>HIV Clinical Trials</i> , 2004, 5, 91-98. | 2.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 217 | Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN γ or IL-12. <i>Vaccine</i> , 2004, 23, 188-197. | 3.8 | 47 |
| 218 | No effect of rosiglitazone for treatment of HIV-1 lipodystrophy: randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2004, 363, 429-438. | 13.7 | 241 |
| 219 | Reversibility of lipodystrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir. <i>Aids</i> , 2004, 18, 1029-1036. | 2.2 | 261 |
| 220 | Three-Year Durability of Dual-Nucleoside Versus Triple-Nucleoside Therapy in a Thai Population With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 693-701. | 2.1 | 11 |
| 221 | HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. <i>HIV Medicine</i> , 2003, 4, 293-301. | 2.2 | 181 |
| 222 | Selective exclusion of treatment arms in multi-arm randomized clinical trials. <i>Statistics in Medicine</i> , 2003, 22, 19-30. | 1.6 | 7 |
| 223 | An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. <i>Lancet</i> , The, 2003, 361, 726-735. | 13.7 | 415 |
| 224 | Chemokine receptor genotype and response to interleukin-2 therapy in HIV-1-infected individuals. <i>Clinical Immunology</i> , 2003, 106, 36-40. | 3.2 | 4 |
| 225 | Combined Analysis of Two-Year Follow-Up from Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: OzCombo 1 and 2. <i>HIV Clinical Trials</i> , 2003, 4, 252-261. | 2.0 | 28 |
| 226 | Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. <i>Aids</i> , 2003, 17, 1889-1896. | 2.2 | 29 |
| 227 | Limited Evolution of HIV Antiretroviral Drug Resistance-Associated Mutations During the Performance of Drug Resistance Testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 32, 57-61. | 2.1 | 12 |
| 228 | An Objective Lipodystrophy Severity Grading Scale Derived From the Lipodystrophy Case Definition Score. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 571-576. | 2.1 | 82 |
| 229 | Quality Assessment Program for Genotypic Antiretroviral Testing Improves Detection of Drug Resistance Mutations. <i>Journal of Clinical Microbiology</i> , 2003, 41, 227-236. | 3.9 | 22 |
| 230 | Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study. <i>HIV Clinical Trials</i> , 2002, 3, 177-185. | 2.0 | 45 |
| 231 | HIV medicine. <i>Medical Journal of Australia</i> , 2002, 176, 21-21. | 1.7 | 2 |
| 232 | The Evaluation of Subcutaneous Proleukin $\hat{\text{A}}$ [®] (interleukin-2) in a Randomized International Trial. <i>Contemporary Clinical Trials</i> , 2002, 23, 198-220. | 1.9 | 81 |
| 233 | Regulatory approvals in a large multinational clinical trial. <i>Contemporary Clinical Trials</i> , 2002, 23, 59-66. | 1.9 | 19 |
| 234 | Immunomodulators as adjunctive therapy for HIV-1 infection. <i>Journal of Clinical Virology</i> , 2001, 22, 289-295. | 3.1 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 235 | Closeout of Four Phase II Vanguard Trials and Patient Rollover into a Large International Phase III HIV Clinical Endpoint Trial. <i>Contemporary Clinical Trials</i> , 2001, 22, 42-48. | 1.9 | 12 |
| 236 | Reply. <i>Journal of Infectious Diseases</i> , 2001, 183, 680-680. | 4.0 | 0 |
| 237 | A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. <i>Aids</i> , 2000, 14, 1171-1180. | 2.2 | 76 |
| 238 | A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. <i>Aids</i> , 2000, 14, 2509-2513. | 2.2 | 33 |
| 239 | Clinical trials of antiretroviral therapy in developing countries. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 3-4. | 0.5 | 1 |
| 240 | Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin-2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease. <i>Journal of Infectious Diseases</i> , 2000, 182, 428-434. | 4.0 | 105 |
| 241 | A Randomized, Controlled, Phase II Trial Comparing Escalating Doses of Subcutaneous Interleukin-2 plus Antiretrovirals versus Antiretrovirals Alone in Human Immunodeficiency Virus-Infected Patients with CD4+Cell Counts $\geq 350/\text{mm}^3$. <i>Journal of Infectious Diseases</i> , 2000, 181, 1614-1621. | 4.0 | 67 |
| 242 | Lipodystrophy following antiretroviral therapy of primary HIV infection. <i>Aids</i> , 2000, 14, 2406-2407. | 2.2 | 46 |
| 243 | Latent reservoirs of HIV infection: Flushing with IL-2?. <i>Nature Medicine</i> , 1999, 5, 611-612. | 30.7 | 8 |
| 244 | Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. <i>Clinical and Experimental Immunology</i> , 1998, 113, 85-91. | 2.6 | 31 |
| 245 | Therapeutic Strategies for HIV Infection – Time to Think Hard. <i>New England Journal of Medicine</i> , 1998, 339, 1319-1321. | 27.0 | 30 |
| 246 | Outpatient Continuous Intravenous Interleukin-2 or Subcutaneous, Polyethylene Glycol-Modified Interleukin-2 in Human Immunodeficiency Virus-Infected Patients: A Randomized, Controlled, Multicenter Study. <i>Journal of Infectious Diseases</i> , 1998, 178, 992-999. | 4.0 | 95 |
| 247 | Safety and Immunogenicity of UBI HIV-1MN Octameric V3 Peptide Vaccine Administered by Subcutaneous Injection. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 29-32. | 1.1 | 33 |
| 248 | Immune reconstitution in HIV infection. <i>Current Opinion in Immunology</i> , 1997, 9, 568-572. | 5.5 | 39 |
| 249 | Drug companies have a duty to continue treatment. <i>BMJ: British Medical Journal</i> , 1997, 314, 889-889. | 2.3 | 3 |
| 250 | Immune-based therapies in HIV infection. <i>Aids</i> , 1996, 10, S159-164. | 2.2 | 16 |
| 251 | CD8+ Lymphocyte Responses to Antiretroviral Therapy of HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 13, 320-326. | 0.3 | 49 |
| 252 | Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection. <i>Australian and New Zealand Journal of Medicine</i> , 1995, 25, 344-349. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Studies on the hyperplasia (â€˜regenerationâ€™) of the rat liver following partial hepatectomy. Changes in lipid peroxidation and general biochemical aspects. <i>Biochemical Journal</i> , 1990, 265, 51-59. | 3.7 | 46 |
| 254 | Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour. <i>Biochemical Journal</i> , 1988, 250, 247-252. | 3.7 | 132 |
| 255 | Effects of Î±-Tocopherol on Carbon Tetrachloride Metabolism in Rat Liver Microsomes. <i>Free Radical Research Communications</i> , 1987, 3, 325-330. | 1.8 | 27 |
| 256 | The effect of cimetidine and ranitidine on paracetamol glucuronidation and sulphation in cultured rat hepatocytes. <i>Biochemical Pharmacology</i> , 1985, 34, 1415-1421. | 4.4 | 23 |
| 257 | Prospective evidence that HIV lipotrophy and visceral adiposity are partially independent processes. <i>Open Access Journal of Clinical Trials</i> , 0, , 1. | 1.5 | 0 |